Prognostic value of baseline human immunodeficiency virus type 1 DNA measurement for disease progression in patients receiving nucleoside therapy

Camlin Tierney; Janet L. Lathey; Cindy Christopherson; Daniel M. Bettendorf; Richard T. D'Aquila; Scott M. Hammer; David A. Katzenstein

doi:10.1086/345870

Prognostic value of baseline human immunodeficiency virus type 1 DNA measurement for disease progression in patients receiving nucleoside therapy

Camlin Tierney^*, Janet L. Lathey, Cindy Christopherson, Daniel M. Bettendorf, Richard T. D'Aquila, Scott M. Hammer, David A. Katzenstein

^*Corresponding author for this work

Medicine, Infectious Diseases Division

Research output: Contribution to journal › Article › peer-review

42 Scopus citations

Abstract

Human immunodeficiency virus (HIV) type 1 DNA assay data were obtained at baseline from 111 HIV-1-positive subjects who were treated with nucleosides. Higher baseline DNA level, HIV-1 RNA level, and infectious titer were comparably associated with an increased hazard of disease progression (each P < .03). Only DNA level was significantly associated with survival (adjusted hazard ratio for 1 log₁₀ higher level, 3.99; 95% confidence interval, 1.44-11.09; P = .008).

Original language	English (US)
Pages (from-to)	144-148
Number of pages	5
Journal	Journal of Infectious Diseases
Volume	187
Issue number	1
DOIs	https://doi.org/10.1086/345870
State	Published - Jan 1 2003

ASJC Scopus subject areas

Immunology and Allergy
Infectious Diseases

Access to Document

10.1086/345870

Fingerprint Dive into the research topics of 'Prognostic value of baseline human immunodeficiency virus type 1 DNA measurement for disease progression in patients receiving nucleoside therapy'. Together they form a unique fingerprint.

Cite this

Tierney, Camlin ; Lathey, Janet L. ; Christopherson, Cindy ; Bettendorf, Daniel M. ; D'Aquila, Richard T. ; Hammer, Scott M. ; Katzenstein, David A. / Prognostic value of baseline human immunodeficiency virus type 1 DNA measurement for disease progression in patients receiving nucleoside therapy. In: Journal of Infectious Diseases. 2003 ; Vol. 187, No. 1. pp. 144-148.

@article{86f6f59627654918a97001d567f52ded,

title = "Prognostic value of baseline human immunodeficiency virus type 1 DNA measurement for disease progression in patients receiving nucleoside therapy",

abstract = "Human immunodeficiency virus (HIV) type 1 DNA assay data were obtained at baseline from 111 HIV-1-positive subjects who were treated with nucleosides. Higher baseline DNA level, HIV-1 RNA level, and infectious titer were comparably associated with an increased hazard of disease progression (each P < .03). Only DNA level was significantly associated with survival (adjusted hazard ratio for 1 log10 higher level, 3.99; 95% confidence interval, 1.44-11.09; P = .008).",

author = "Camlin Tierney and Lathey, {Janet L.} and Cindy Christopherson and Bettendorf, {Daniel M.} and D'Aquila, {Richard T.} and Hammer, {Scott M.} and Katzenstein, {David A.}",

note = "Funding Information: Financial support: National Institutes of Health (grants AI-38855 to C.T. and D.M.B., AI-27670 and AI-36214 to J.L.L., AI-29193 and AI-46339 to R.T.D., and AI-46386, AI-48013, and AI-42848 to S.M.H.).",

year = "2003",

month = jan,

day = "1",

doi = "10.1086/345870",

language = "English (US)",

volume = "187",

pages = "144--148",

journal = "Journal of Infectious Diseases",

issn = "0022-1899",

publisher = "Oxford University Press",

number = "1",

}

Prognostic value of baseline human immunodeficiency virus type 1 DNA measurement for disease progression in patients receiving nucleoside therapy. / Tierney, Camlin; Lathey, Janet L.; Christopherson, Cindy; Bettendorf, Daniel M.; D'Aquila, Richard T.; Hammer, Scott M.; Katzenstein, David A.

In: Journal of Infectious Diseases, Vol. 187, No. 1, 01.01.2003, p. 144-148.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Prognostic value of baseline human immunodeficiency virus type 1 DNA measurement for disease progression in patients receiving nucleoside therapy

AU - Tierney, Camlin

AU - Lathey, Janet L.

AU - Christopherson, Cindy

AU - Bettendorf, Daniel M.

AU - D'Aquila, Richard T.

AU - Hammer, Scott M.

AU - Katzenstein, David A.

N1 - Funding Information: Financial support: National Institutes of Health (grants AI-38855 to C.T. and D.M.B., AI-27670 and AI-36214 to J.L.L., AI-29193 and AI-46339 to R.T.D., and AI-46386, AI-48013, and AI-42848 to S.M.H.).

PY - 2003/1/1

Y1 - 2003/1/1

N2 - Human immunodeficiency virus (HIV) type 1 DNA assay data were obtained at baseline from 111 HIV-1-positive subjects who were treated with nucleosides. Higher baseline DNA level, HIV-1 RNA level, and infectious titer were comparably associated with an increased hazard of disease progression (each P < .03). Only DNA level was significantly associated with survival (adjusted hazard ratio for 1 log10 higher level, 3.99; 95% confidence interval, 1.44-11.09; P = .008).

AB - Human immunodeficiency virus (HIV) type 1 DNA assay data were obtained at baseline from 111 HIV-1-positive subjects who were treated with nucleosides. Higher baseline DNA level, HIV-1 RNA level, and infectious titer were comparably associated with an increased hazard of disease progression (each P < .03). Only DNA level was significantly associated with survival (adjusted hazard ratio for 1 log10 higher level, 3.99; 95% confidence interval, 1.44-11.09; P = .008).

UR - http://www.scopus.com/inward/record.url?scp=0037217732&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037217732&partnerID=8YFLogxK

U2 - 10.1086/345870

DO - 10.1086/345870

M3 - Article

C2 - 12508159

AN - SCOPUS:0037217732

VL - 187

SP - 144

EP - 148

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

SN - 0022-1899

IS - 1

ER -